What the FDA labels say about taking them together
Lomitapide and ritonavir
Ritonavir's FDA label of July 23, 2026 names lomitapide in its contraindications section; the lomitapide label PlainMeds reads does not name ritonavir. The ritonavir label: “… inhibitor for details on co-administration with atorvastatin and rosuvastatin. Lomitapide is a sensitive substrate for CYP3A4 metabolism. …”
Check it at the source: the lomitapide FDA label on DailyMed (effective March 30, 2026, Chiesi USA, Inc.); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the lomitapide label say about ritonavir?
Lomitapide's label (effective March 30, 2026) does not name ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Juxtapid), Chiesi USA, Inc., effective March 30, 2026 (SPL set 61a0be9d-ee58-43e0-b5cb-141011835081), via openFDA; the full label on DailyMed
What does the ritonavir label say about lomitapide?
Ritonavir label, contraindications… lurasidone, pimozide ○ Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine ○ GI Motility Agent: cisapride ○ HMG-CoA Reductase Inhibitors: lovastatin, simvastatin ○ Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide ○ Non-opioid Analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine ○ PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension ○ Sedative/Hypnotics: triazolam, orally administered midazolam
Ritonavir label, drug interactionsConcomitant Drug Class/Drug Name: Lipid-modifying agents HMG-CoA Reductase Inhibitor: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide; Effect on Concentration of Ritonavir or Concomitant Drug: ↑ lovastatin ↑ simvastatin ↑ atorvastatin ↑ rosuvastatin ↑ lomitapide; Clinical Comment: Contraindicated due to potential for myopathy including rhabdomyolysis [see Contraindications () ]. …
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lomitapide | Ritonavir | |
|---|---|---|
| Labeled for | High cholesterol | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once